Laying the Foundation for Clinically Actionable Genomic Subtyping in Diffuse Large B-cell Lymphoma

Diffuse large B-cell lymphoma (DLBCL) is clinically and genetically heterogeneous. The existence of genetically defined subtypes with therapeutic implications is clear. Additional considerations that are yet to be fully resolved include defining boundaries between discrete classes, relevant molecular data types, and handling of unclassifiable/composite cases. In this review, we juxtapose points of view on the topic from experts in the field, outline practical workflow considerations, and distill lessons from clinical trials. These synthesize experimental design and analytic considerations that inform the development and evaluation of clinically relevant DLBCL subtyping approaches. SIGNIFICANCE: The most meaningful way to stratify DLBCL remains unresolved, and this represents a significant barrier to adopting a precision medicine paradigm.

Authors

Institutions

Publication Details

Journal
Blood Cancer Discovery
Published
2026-05-12
DOI
https://doi.org/10.1158/2643-3230.bcd-25-0327
Primary Topic
Lymphoma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Laying the Foundation for Clinically Actionable Genomic Subtyping in Diffuse Large B-cell Lymphoma

Louis M. Staudt, W Zhao, Ryan D. Morin, David W. Scott et al.
Blood Cancer Discovery
Lymphoma Diagnosis and Treatment
article

Laying the Foundation for Clinically Actionable Genomic Subtyping in Diffuse Large B-cell Lymphoma

Louis M. Staudt, W Zhao, Ryan D. Morin, David W. Scott, Margaret A. Shipp, Ash A. Alizadeh, Riccardo Dalla-Favera, Daniel J. Hodson
article en

Abstract

Diffuse large B-cell lymphoma (DLBCL) is clinically and genetically heterogeneous. The existence of genetically defined subtypes with therapeutic implications is clear. Additional considerations that are yet to be fully resolved include defining boundaries between discrete classes, relevant molecular data types, and handling of unclassifiable/composite cases. In this review, we juxtapose points of view on the topic from experts in the field, outline practical workflow considerations, and distill lessons from clinical trials. These synthesize experimental design and analytic considerations that inform the development and evaluation of clinically relevant DLBCL subtyping approaches. SIGNIFICANCE: The most meaningful way to stratify DLBCL remains unresolved, and this represents a significant barrier to adopting a precision medicine paradigm.

Blood Cancer Discovery
National Institutes of Health (US), Simon Fraser University (CA), Shanghai Jiao Tong University (CN), Wellcome/MRC Cambridge Stem Cell Institute (GB), Spinal Cord Injury BC (CA), Dana-Farber Cancer Institute (US), Stem Cell Institute (PA), National Cancer Institute (US), Cancer Genetics (United States) (US), Institute of Natural Science (KP), Stanford University (US)
Lymphoma Research Foundation, Wellcome, Leukemia and Lymphoma Society, Cancer Research UK, National Institute for Health and Care Research, Terry Fox Research Institute, National Institutes of Health, Canadian Institutes of Health Research
Openalex Percentile: Top 5%
Lymphoma Diagnosis and Treatment
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.